Scion is contributing to the fight against SARS-CoV-2 by helping develop and manufacture an experimental COVID-19 vaccine.

CVC (COVID-19 Vaccine Corporation), formed by New Zealand experts in vaccine development and biotechnology, is working on a vaccine against SARS-CoV-2, which causes COVID-19.

CVC has designed vaccine antigens that create cell-mediated immune responses specifically to SARS-CoV-2. It is one of the few vaccines of this type being developed in the world today. CVC’s vaccine is designed to be insensitive to viral mutations/variants and to provide protection to the global population. CVC’s vaccine would be given in addition or in conjunction with the COVID-19 vaccines currently being administered, to provide broader protection against current and future variants.

Scion’s biotechnology group has worked with CVC’s scientists to fast-track the manufacture of two vaccine prototypes that CVC has taken into pre-clinical testing. Scion’s expertise, resources and ability to work flexibly in the face of a global health challenge, have been essential to facilitating the CVC vaccine project.